Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why TG Therapeutics Inc. Shares Jumped

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of TG Therapeutics (NASDAQ: TGTX  ) , a clinical-stage biopharmaceutical company focused on developing therapies to treat cancer and other unmet disease areas, surged as much as 19% after announcing a global licensing agreement with Ligand Pharmaceuticals (NASDAQ: LGND  ) .

So what: Under the terms of the deal, TG Therapeutics is licensing the global rights to Ligand's IRAK4 inhibitor research program. Specifically, IRAK4 is a "key signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in patients with Waldenstrom's Macroglobulinemia, a rare B-cell cancer, as well as a sub-set of patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia." As noted, IRAK4 inhibition could also provide benefits to other autoimmune disorders.

In exchange for licensing rights to this currently preclinical program TG Therapeutics will give Ligand an upfront licensing fee of 125,000 unregistered common stage of TG stock. TG will also pay Ligand development and sales-based milestones, as well as a mid-to-high single-digit royalty on net sales should any therapies be approved.

Now what: I believe this is a necessary move for TG Therapeutics which needs to find a way to expand its pipeline and give itself more chances to "hit a home run." Currently, it only has three clinical studies under way – although TG-1101 as a late-stage treatment for chronic lymphocytic leukemia and mantle cell lymphoma in combination with Pharmacyclics' Imbruvica delivered stellar results in the early going. Still, justifying a $400 million valuation based on the results of a single phase 1 study and the idea that it has two additional phase 1's under way might be a bit of a stretch. It admittedly licensed the IRAK4 program for a small sum (just 125,000 shares), so the deal itself looks promising on paper. The big question going forward is whether or not TG Therapeutics can justify its valuation with clinical follow-through over the next couple of years.

TG Therapeutics may have soared today, but keeping pace with this top stock over the long haul might prove impossible! 
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3006589, ~/Articles/ArticleHandler.aspx, 8/30/2015 6:06:03 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated 1 day ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
LGND $95.04 Up +0.79 +0.84%
Ligand Pharmaceuti… CAPS Rating: ***
TGTX $13.02 Up +0.40 +3.17%